Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers
- 1 August 2011
- Vol. 29 (37), 6313-6320
- https://doi.org/10.1016/j.vaccine.2011.05.047
Abstract
No abstract availableKeywords
Funding Information
- Defense Advanced Research Projects Administration
- U.S. Army Research Office
This publication has 36 references indexed in Scilit:
- Systemic but not mucosal immunity induced by AVA prevents inhalational anthraxMicrobes and Infection, 2007
- Pharmacokinetic Considerations and Efficacy of Levofloxacin in an Inhalational Anthrax (Postexposure) Rhesus Monkey ModelAntimicrobial Agents and Chemotherapy, 2006
- Immunological Correlates for Protection against Intranasal Challenge of Bacillus anthracis Spores Conferred by a Protective Antigen-Based Vaccine in RabbitsInfection and Immunity, 2006
- An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability programPharmacoepidemiology and Drug Safety, 2005
- Mass Value Assignment of Total and Subclass Immunoglobulin G in a Human Standard Anthrax Reference SerumClinical and Vaccine Immunology, 2004
- Selection of Bacillus anthracis isolates resistant to antibioticsJournal of Antimicrobial Chemotherapy, 2004
- Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistanceJournal of Antimicrobial Chemotherapy, 2004
- Validation of the anthrax lethal toxin neutralization assayBiologicals, 2004
- In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activityJournal of Antimicrobial Chemotherapy, 2004
- CpG Motifs in Bacterial DNA and Their Immune EffectsAnnual Review of Immunology, 2002